Drug-Resistant HIV on Rise as Medicines Misused

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

Drug-Resistant HIV on Rise as Medicines Misused

Newsday (N.Y.) (12.18.01) - Tuesday, December 18, 2001
Laurie Garrett

Widespread misuse of HIV drugs has led to drug resistance in at least half the US population under treatment, scientists are reporting today. Contrary to forecasts made in 1996 when combination drug therapy was introduced, it is not the poor and IV drug users who have the highest rates of resistance because of failure to properly take the drugs. Rather, it is white, gay, fully insured, highly educated men who carry the most highly drug-resistant viruses.

A national survey of some 2,000 HIV patients, conducted by RAND Corp. and the University of California at San Diego (UCSD), found that 64 percent of patients are now getting less benefit from their drug cocktails than they were two or three years ago, as measured by rising levels of the virus in their blood. Among those with rising HIV blood levels, 78 percent have drug- resistant HIV. Even newly infected treatment-na ve individuals are showing astonishing levels of drug resistance - one out of five carry drug-resistant viruses.

This means that by the most conservative possible reckoning of the data, "half of the people under care in the United States right now have resistant virus. It's quite frightening," said senior researcher Dr. Doug Richman of UCSD. Richman will present the findings today at the annual Interscience Conference on Antibacterial Agents and Chemotherapy meeting in Chicago (www.icaac.org).

"What is not politically correct to say in public is that both providers and patients are using these drugs suboptimally," Richman said. Well-educated patients and their doctors closely follow reseach and trends in highly active antiretroviral therapy (HAART), changing treatment plans often in search of minimal side effects, ease of use and viral suppression. But each switch increases the likelihood of mutant, drug-resistant HIV.

Richman fears this continued pattern of chaotic use means "we'll end up recapitulating the antibiotic story," referring to antibiotic-resistant bacteria. Hastening the emergence of resistance, HIV mutates more rapidly than bacteria, and HAART must be taken for the rest of the patient's life. Because the size of the HIV-positive population in wealthy nations is small, "the incentive for the pharmaceutical industry to develop drugs against resistant HIV may not be there the way it is for antibiotics," Richman said.
011218
AD012186

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.